在免疫治疗时代，贝伐珠单抗似乎正在失去其在 NSCLC 治疗算法中的地位。这项工作的目的是试图确定联合方案中贝伐珠单抗治疗 NSCLC 的优点和缺点。我们在 PubMed 和 Google Scholar 中进行了文献检索，回顾了有关 NSCLC 贝伐珠单抗治疗（无论有或没有驱动突变）的最重要主题，包括检查点抑制剂的试验。特别强调了中枢神经系统转移患者治疗数据的分析。贝伐珠单抗是一种抗血管生成化合物，其添加到化疗中，在非小细胞肺癌的治疗中取得了第一个重大突破。然而，在过去十年左右的时间里，联合免疫治疗方案的使用抑制了贝伐单抗的使用和新知识的获取。较新的数据主要与贝伐单抗治疗 EGFR 阳性 NSCLC 患者有关，只有少数大型研究调查贝伐单抗和检查点抑制剂的联合使用。基本任务仍然是确定贝伐单抗在治疗算法中的地位。

In the era of immunotherapy, bevacizumab seems to be losing its place in NSCLC treatment algorithms. The aim of this work is to try to define the advantages and disadvantages of NSCLC treatment with bevacizumab in combination regimens.We conducted a literature search in PubMed and Google Scholar to review the most important topics regarding bevacizumab treatment in NSCLC, with or without driver mutations, including trials with checkpoint inhibitors. Special emphasis was placed on the analysis of data on the treatment of patients with CNS metastases.Bevacizumab is an antiangiogenic compound whose addition to chemotherapy made the first major breakthrough in the treatment of NSCLC. However, for the last 10 years or so, the use of combination immunotherapy regimens has suppressed the use and acquisition of new knowledge about bevacizumab. Newer data are primarily related to the treatment of EGFR-positive NSCLC patients with bevacizumab, with only a few larger studies investigating the use of a combination of bevacizumab and checkpoint inhibitors. The basic task remains to define the place of bevacizumab in treatment algorithms.